<DOC>
	<DOCNO>NCT01790152</DOCNO>
	<brief_summary>This clinical trial study effect dexrazoxane hydrochloride biomarkers associate cardiomyopathy heart failure cancer treatment . Studying sample blood laboratory patient receive dexrazoxane hydrochloride may help doctor learn effect dexrazoxane hydrochloride cell . It may also help doctor understand well patient respond treatment .</brief_summary>
	<brief_title>Effects Dexrazoxane Hydrochloride Biomarkers Associated With Cardiomyopathy Heart Failure After Cancer Treatment</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine whether patient randomize experimental dexrazoxane hydrochloride ( DRZ ) arm decrease marker cardiomyopathy/heart failure ( CHF ) compare patient standard arm . II . To evaluate whether cardioprotective effect DRZ modify anthracycline ( anthracycline analogue GPX-150 ) dose , chest radiation , demographic factor ( age cancer diagnosis , current age , sex ) . SECONDARY OBJECTIVES : I . To determine whether patient DRZ arm experience differential rate overall-survival event-free survival compare standard therapy arm . II . To determine whether project quality-adjusted life year ( QALY ) differ randomization status , account premature cardiac disease , primary disease relapse , second cancer . OUTLINE : Patients complete diagnostic symptom checklist , undergo physical exam , echocardiogram , collection serum biomarker testing , 6 minute walk test , complete quality life , family history , physical activity , smoking questionnaire .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Cardiomyopathies</mesh_term>
	<mesh_term>Leukemia , T-Cell</mesh_term>
	<mesh_term>Leukemia-Lymphoma , Adult T-Cell</mesh_term>
	<mesh_term>Dexrazoxane</mesh_term>
	<mesh_term>Razoxane</mesh_term>
	<criteria>Previously enrol randomize POG 9404 , 9425 , 9426 STRATUM I : Alive continuous first complete remission original cancer ( Tcell leukemia/lymphoma [ POG 9404 ] Hodgkin lymphoma [ POG 9425/9426 ] ) STRATUM I : Not diagnose subsequent malignancy , exception nonmelanomatous skin cancer ( ) ; patient history subsequent nonmelanomatous skin cancer remain eligible STRATUM I : All patient and/or parent legal guardian must sign write informed consent Among patient relapse experienced subsequent malignancy nonmelanomatous skin cancer since original diagnosis , study committee review available data ( Children 's Oncology Group 's [ COG 's ] Statistics Data Center [ SDC ] participate institution ) determine individual patient select Stratum 2 ; recognition local institution sometimes updated relapse/subsequent cancer data SDC , case local data update , local data use preferentially ; study petition Institutional Review Board ( IRB ) specifically waiver consent include relapse subsequent cancer data obtain exist record analysis secondary aim ; patient select Stratum 2 late relapse subsequent cancer report lack clear confirmation exist record ( either SDC local institution ) STRATUM II : Alive , experienced relapse original cancer and/or develop subsequent cancer ( nonmelanomatous skin cancer ) since original diagnosis STRATUM II : All patient and/or parent legal guardian must sign write informed consent For participant , institutional , Food Drug Administration ( FDA ) , National Cancer Institute ( NCI ) requirement human study must meet ; finally , coordinate center create master list use SDC record local institution patient approach ; patient otherwise appear eligible Stratum 1 2 identified list enrol without prior approval study chair</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>